Investors > ASX Announcements

ASX Announcements

1-Apr-2025	Publication of NeuCA15-3 assay data

31-Mar-2025	IIQ to work with Peter Mac to validate car-exosome therapy

19-Mar-2025	Investor Webinar Presentation

17-Mar-2025	INOVIQ appoints Chief Commercial Officer

21-Feb-2025	Appendix 4D and FY25 Half Year Financial Report

10-Feb-2025	INOVIQ establishes Medical and Scientific Advisory Board

31-Jan-2025	Quarterly Business Update and Appendix 4C - December 2024

16-Dec-2024	Weaponising Exosomes for Breast Cancer treatment

11-Dec-2024	Investor Webinar Presentation

5-Dec-2024	Disease Specificity study completed for NeuCA15-3 test

3-Dec-2024	EXO-OC test delivers outstanding performance

28-Nov-2024	2024 AGM Results of Meeting

28-Nov-2024	2024 AGM CEO Presentation

26-Nov-2024	INOVIQ receives $1m RDTI refund

31-Oct-2024	Quarterly Business Update and Appendix 4C - September 2024

25-Oct-2024	Notice of Annual General Meeting/Proxy Form

20-Sep-2024	2024 Annual Report

3-Sep-2024	Mary Harney - Non-Executive Director

20-Aug-2024	NEURO-NET validated in Parkinson's

19-Aug-2024	EGM and Webinar Broadcast

30-Jul-2024	Quarterly Activities Report and Appendix 4C - June 2024

19-Jul-2024	Notice of Extraordinary General Meeting

5-Jul-2024	Successful completion of Share Purchase Plan

19-Jun-2024	Target Market Determination (not ASX released)

19-Jun-2024	INOVIQ lodges SPP and Options Prospectus

12-Jun-2024	Investor Presentation

12-Jun-2024	INOVIQ isolates brain-derived exosomes in Alzheimer's

12-Jun-2024	INOVIQ completes $7m placement

11-Jun-2024	INOVIQ MST Access Investor Presentation

7-Jun-2024	Trading Halt

3-Jun-2024	Breakthrough Exosome Therapy

30-Apr-2024	Quarterly Activities Report and Appendix 4C - March 2024

19-Apr-2024	Ovarian Cancer Test Validation

17-Apr-2024	INOVIQ Investor Update

16-Apr-2024	INOVIQ Investor Webinar

15-Apr-2024	INOVIQ and Promega sign Global EXO-NET Agreement

12-Apr-2024	INOVIQ (ASX:IIQ) - Webinar Presentation

12-Apr-2024	INOVIQ ShareCafe Investor Presentation

20-Mar-2024	INOVIQ expands exosome IP

19-Mar-2024	Exosomes for non-invasive pre-natal testing

23-Feb-2024	Appendix 4D and FY24 Half Year Financial Report

22-Feb-2024	INOVIQ detects 19% more breast cancers than leading test

31-Jan-2024	Appendix 4C and Quarterly Activities Report - December 2023

29-Nov-2023	2023 AGM Results of Meeting

29-Nov-2023	2023 AGM CEO Presentation

16-Nov-2023	Bell Potter Healthcare Conference Investor Presentation

8-Nov-2023	ANSEV Meeting Presentations

30-Oct-2023	Appendix 4C and Quarterly Activities Report - September 2023

27-Oct-2023	Notice of Annual General Meeting/Proxy Form

11-Oct-2023	INOVIQ Board expanded - David Williams to become Chairman

27-Sep-2023	2023 Annual Report

20-Sep-2023	ASX Small and Mid-Cap Conference Investor Presentation

6-Sep-2023	IFPA 2023 Conference Presentation and Award for INOVIQ CSO

5-Sep-2023	IIQ and ResearchDx sign USA EXO-NET Services Agreement

30-Aug-2023	Appendix 4E and Preliminary Financial Report

9-Aug-2023	EXO-OC PROGRAM COMPLETES SERUM EQUIVALENCE STUDY

1-Aug-2023	INOVIQ Investor Briefing

28-Jul-2023	Appendix 4C and Quarterly Activities Report - June 2023

6-Jul-2023	INOVIQ and Promega announce Global Joint Marketing Agreement

29-Jun-2023	SubB2M/CA15.3 Clinical Validation Data Investor Presentation

27-Jun-2023	INOVIQ Investor Briefing

27-Jun-2023	Excellent Clinical Data for SubB2M/CA15-3 Breast Cancer Test

19-May-2023	ISEV Meeting Presentations

28-Apr-2023	Appendix 4C and Quarterly Activities Report - March 2023

19-Apr-2023	INOVIQ to present new EXO-NET data at ISEV Annual Meeting

24-Feb-2023	Appendix 4D and Half Year Financial Report

8-Feb-2023	Positive results for SubB2M Breast Cancer Test

31-Jan-2023	Appendix 4C & Quarterly Activities Report - December 2022

14-Dec-2022	Resignation of Director

13-Dec-2022	Positive EXO-NET Results in Ovarian Cancer

5-Dec-2022	MST Access Diagnostics Forum Presentation

30-Nov-2022	Change in substantial holding

28-Nov-2022	Results of 2022 Annual General Meeting

28-Nov-2022	CEO AGM Presentation

28-Nov-2022	INOVIQ Settles Legal Proceedings

25-Nov-2022	Commercial and R&D Update

10-Nov-2022	Healthcare Conference Investor Presentation

4-Nov-2022	Appendix 4C - Statement pursuant to Listing Rule 4.7C.3

28-Oct-2022	IIQ Appendix 4C & Quarterly Activities Report-September 2022

27-Oct-2022	Canadian Patent Granted for BARD1 Technology

27-Oct-2022	Investor Presentation

27-Oct-2022	Notice of Annual General Meeting

14-Oct-2022	Receipt of R&D Tax Incentive Refund

13-Oct-2022	INOVIQ to Develop SubB2M-Based Test on Nicoya SPR Platform

12-Oct-2022	Appendix 4G and Corporate Governance Statement

6-Oct-2022	Appointment/Resignation of CFO and Company Secretary

3-Oct-2022	Notification of cessation of securities - IIQ

3-Oct-2022	Notice required under listing rule 3.13.1

28-Sep-2022	2022 Annual Report and update on results

30-Aug-2022	Appendix 4E and Preliminary Financial Report

9-Aug-2022	IIQ Investor Presentation

4-Aug-2022	INOVIQ Investor Briefing Invitation - June 2022 Quarter

27-Jul-2022	IIQ Appendix 4C & Quarterly Activities Report - June 2022

26-Jul-2022	Positive SubB2M IHC Results for Melanoma

22-Jul-2022	hTERT US Patent Granted

21-Jul-2022	INOVIQ Engages Sales Team to Accelerate EXO-NET Roll-out

1-Jul-2022	SubB2M US Patent Grant and Program Update

27-May-2022	INOVIQ&University of Sydney Present New EXO-NET Data at ISEV

16-May-2022	Change of Director's Interest - Philip Powell

10-May-2022	IIQ Investor Presentation

9-May-2022	Change of Director's Interest - Dr Geoffrey Cumming

4-May-2022	Change of Director's Interest - Philip Powell

3-May-2022	INOVIQ Investor Briefing Invitation

3-May-2022	Australian Patent Granted for SubB2M Technology

2-May-2022	INOVIQ Key Manufacturing Agreement to Advance SubB2M tests

29-Apr-2022	IIQ Appendix 4C & Quarterly Activities Report - March 2022

26-Apr-2022	INOVIQ CSO Co-Authors Scientific Statement on Exosomes

21-Apr-2022	Notification of cessation of securities - IIQ

6-Apr-2022	Updated Investor Presentation

6-Apr-2022	SubB2M Paper Published in BMC Cancer Journal

5-Apr-2022	INOVIQ Engages ResearchDX to Develop & Validate SubB2M-Tests

1-Apr-2022	INOVIQ & UQ Collaborate on Exosome-based Ovarian Cancer Test

28-Mar-2022	Update on Legal Proceedings and BARD1 Autoantibody Program

25-Feb-2022	Appendix 4D and Half Year Financial Report

23-Feb-2022	Brazilian Patent Issued for Lung & Colorectal Cancer

3-Feb-2022	Updated Investor Presentation

31-Jan-2022	Notification regarding unquoted securities - IIQ

31-Jan-2022	Appendix 4C & Quarterly Activities Report

17-Jan-2022	US Patent Issued - BARD1 Breast & Ovarian Cancer Diagnosis

10-Jan-2022	INOVIQ Awarded Additional BTB Funding to Develop SubB2M test

29-Dec-2021	INOVIQ Appendix 4G and Corporate Governance Statement

24-Dec-2021	Chinese Patent Issued in BARD1 Patent Family for Lung Cancer

22-Dec-2021	Appendix 3Y - Change of Director's Interest Notice x 4

13-Dec-2021	Notification regarding unquoted securities - IIQ

8-Dec-2021	BARD1 Changes its Name to INOVIQ

7-Dec-2021	Cleansing Notice - Issued of Four Shares - Resolution 5 AGM

7-Dec-2021	Application for quotation of securities - BD1

2-Dec-2021	Application for quotation of securities - BD1

30-Nov-2021	Results of 2021 Annual General Meeting

29-Nov-2021	AGM Presentation

29-Nov-2021	New BARD1 Exosome Liquid Biopsy Project

25-Nov-2021	Application for quotation of securities - BD1

22-Nov-2021	Notification regarding unquoted securities - BD1

12-Nov-2021	US Patent Issued - BARD1 Patent Family Lung Cancer Diagnosis

10-Nov-2021	EXO-NET ANZSEV Presentation

10-Nov-2021	BARD1 Presenting at Bell Potter Healthcare Conference

10-Nov-2021	EXO-NET Presented at Virtual ANZSEV Symposium

9-Nov-2021	Jobkeeper Payment Notification

1-Nov-2021	Notice of Annual General Meeting/Proxy Form

29-Oct-2021	Ceasing to be a substantial holder

29-Oct-2021	Appendix 4G and Corporate Governance Statement

29-Oct-2021	Appendix 4C & Quarterly Activities Report

22-Oct-2021	Change of Director's Interest - Philip Powell

20-Oct-2021	Amended Remuneration Table Directors Report

11-Oct-2021	Notice required under listing rule 3.13.1

1-Oct-2021	Notification of cessation of securities - BD1

29-Sep-2021	2021 Annual Report

16-Sep-2021	BARD1 Appoints New CSO

7-Sep-2021	Notification of cessation of securities - BD1

31-Aug-2021	Appendix 4E and Preliminary Financial Report

27-Aug-2021	Change in substantial holding

27-Aug-2021	Change of Director's Interest - Powell

27-Aug-2021	Change of Director's Interest - Dr Geoffrey Cumming

27-Aug-2021	Change of Director's Interest - Johnston

24-Aug-2021	Notification of cessation of securities - BD1

24-Aug-2021	Appendix 2A

23-Aug-2021	BARD1 Share Purchase Plan Completed Oversubscribed

17-Aug-2021	Proof-of-Concept for SubB2M ELISA-Based Ovarian Cancer Test

30-Jul-2021	BARD1 LODGES SPP AND OPTIONS PROSPECTUS

30-Jul-2021	Appendix 4C & Quarterly Activities Report

29-Jul-2021	Appendix 2A

28-Jul-2021	BARD1 Collaborator Uni of QLD Announces Ovarian Cancer Data

23-Jul-2021	Updated Investor Presentation

23-Jul-2021	Terms of issue of Options

23-Jul-2021	Investor Presentation

23-Jul-2021	Appendix 3B

23-Jul-2021	BARD1 $15m Placement to Accelerate Cancer Diagnostic Program

21-Jul-2021	Trading Halt

7-Jul-2021	BARD1 Investor Presentation

29-Jun-2021	BARD1 Autoantibody Test Results for Ovarian Cancer Published

25-Jun-2021	SubB2M Breast Cancer Test Manuscript Submitted

4-Jun-2021	Update on Legal Proceedings

31-May-2021	R&D Tax Incentive Refund Received

25-May-2021	BARD1 Demonstrates Feasibility of SubB2M-Based IHC Test

24-May-2021	BARD1 Files Two New Patents Protecting SubB2M & EXO-NET

19-May-2021	BARD1 EXO-NET Exosome Data Presented at ISEV2021 Conference

18-May-2021	BARD1 Launches its RUO EXO-NET Product

30-Apr-2021	Appendix 4C and Quarterly Activities Report

29-Apr-2021	Positive Results from the BARD1 Autoantibody Assay

16-Apr-2021	Appendix 3G - Long Term Incentive Options Issued to CEO

13-Apr-2021	BARD1 Signs Option Agreement for Type 3C Diabetes Test

19-Mar-2021	Appendix 2A

16-Mar-2021	Positive Results Evaluation of EXO-NET in Pancreatic Cancer

15-Mar-2021	Appendix 2A

15-Mar-2021	Australian Patent Granted for hTERT

12-Mar-2021	BARD1 Achieves hTERT Registration and First Order in Korea

2-Mar-2021	Appendix 2A

1-Mar-2021	Change in substantial holding

1-Mar-2021	Ceasing to be a substantial holder

26-Feb-2021	Appendix 4D and Half-year financial report

24-Feb-2021	Commencement of Legal Proceedings Against BARD1

23-Feb-2021	Appendix 2A

18-Feb-2021	Ceasing to be a substantial holder

17-Feb-2021	Becoming a substantial holder

15-Feb-2021	Excellent SubB2M Breast Cancer Test Data

11-Feb-2021	Outstanding SubB2M Ovarian Cancer Test Data

9-Feb-2021	Change of Auditor

29-Jan-2021	Appendix 4C & Quarterly Activities Report

28-Jan-2021	U.S. Patent Granted for NET Technology for Exosome Capture

15-Jan-2021	Final Director's Interest Notice - Dr Irminger-Finger

15-Jan-2021	Dr Irminger steps down from Board, continues as Consultant

8-Dec-2020	Change of Director's Interest Notice - Cumming

3-Dec-2020	Change of Director's Interest Notice - Powell

3-Dec-2020	Change of Director's Interest Notice - Johnston

2-Dec-2020	Final Director's Interest Notice - Helen Fisher

2-Dec-2020	Patent Granted in China for hTERT

1-Dec-2020	Further Detail on BARD1's US Sales Strategy

1-Dec-2020	Trading Halt

1-Dec-2020	Pause in Trading

27-Nov-2020	Results of Meeting

26-Nov-2020	AGM & CEO Presentations and Chairman's Transcript

26-Nov-2020	Consolidation/Split - BD1

25-Nov-2020	Helen Fisher Steps Down from BARD1 Board

23-Nov-2020	BARD1 Gains New High-volume Customer for its hTERT Test

30-Oct-2020	Appendix 4C and Quarterly Activities Report

27-Oct-2020	Notice of Annual General Meeting/Proxy Form

19-Oct-2020	Notice of AGM ASX Listing Rule 3.13.1

23-Sep-2020	Successful BARD1 Kit Evaluation

3-Sep-2020	BARD1 Awarded BTB Funding to Develop Breast Cancer Test

31-Aug-2020	Revised Securities Trading Policy

25-Aug-2020	Appendix 4G and Corporate Governance Statement

25-Aug-2020	Appendix 4E and Annual Report to Shareholders

24-Aug-2020	Change of Director's Interest - Helen Fisher

24-Aug-2020	Change of Director's Interest - Dr Geoffrey Cumming

10-Aug-2020	European Patent Validated

4-Aug-2020	Change in substantial holding

4-Aug-2020	Initial Director's Interest Notice - Fisher

4-Aug-2020	Initial Director's Interest Notice - Cumming

3-Aug-2020	Change of Director's Interest Notice - Powell

3-Aug-2020	Change of Director's Interest Notice - Johnston

3-Aug-2020	Final Directors Interest - Gunzburg

3-Aug-2020	Change in substantial holding

30-Jul-2020	Quarterly Business Update & Appendix 4C

29-Jul-2020	Appendix 2A - Issue of Scheme Shares

28-Jul-2020	BARD1 COMPLETES SIENNA ACQUISITION

28-Jul-2020	SDX: Implementation of Scheme of Arrangement

24-Jul-2020	Appointment of Chief Scientific Officer

29-Apr-2020	Quarterly Activities Report & Appendix 4C

20-Apr-2020	Receipt of R&D Tax Incentive Refund

2-Apr-2020	BARD1 Signs Contract with Griffith University

25-Feb-2020	Half Yearly Report and Accounts

30-Jan-2020	Appendix 4C Quarterly Cashflow Report

23-Jan-2020	Appendix 3Y - Cripps

23-Jan-2020	Director Appointment

10-Dec-2019	Details of Company Address

25-Nov-2019	Appendix 3B

25-Nov-2019	Appendix 3Y - Irminger-Finger

14-Nov-2019	Constitution

14-Nov-2019	Results of Meeting

14-Nov-2019	AGM Presentation

30-Oct-2019	Appendix 4C - quarterly

29-Oct-2019	Change in substantial holding

29-Oct-2019	Change in substantial holding

25-Oct-2019	Appendix 3Y - Irminger-Finger

11-Oct-2019	Notice of Annual General Meeting/Proxy Form

8-Oct-2019	Phase 3 Assay Development Milestone Reached

4-Oct-2019	Appendix 3B

3-Oct-2019	Long Term Incentives for CEO

1-Oct-2019	Appendix 3Y - Irminger-Finger

19-Aug-2019	Appendix 4G and Corporate Governance Statement

19-Aug-2019	Appendix 4E and Annual Report to Shareholders

31-Jul-2019	Quarterly Business Update and Appendix 4C

16-Jul-2019	Change in Substantial Shareholding - Irminger-Finger

16-Jul-2019	Appendix 3Y - Powell

16-Jul-2019	Appendix 3Y - Johnston

16-Jul-2019	Appendix 3Y - Irminger-Finger

16-Jul-2019	Appendix 3Y - Gunzburg

12-Jul-2019	Completion of Capital Raising Package

12-Jul-2019	Appendix 3B and Cleansing Notice 708A

10-Jul-2019	Closure of Entitlement Offer and Shortfall Notification

1-Jul-2019	Progress on Assay Development Program

26-Jun-2019	Despatch of Offer Document

19-Jun-2019	603 SSN - Merchant Funds Management Pty Ltd

19-Jun-2019	603 SSN - Jeffrey Emmanuel

19-Jun-2019	603 Initial SSN - Moggs Creek Pty Ltd ATF Moggs Creek S/F

19-Jun-2019	Letters to Shareholders

19-Jun-2019	Appendix 3X - Powell

19-Jun-2019	Appendix 3X - Johnston

19-Jun-2019	Appendix 3Z - Montgomery

18-Jun-2019	Letter to Optionholders

18-Jun-2019	Cleansing Notice Section 708(AA)

18-Jun-2019	Cleansing Notice Section 708(A)

18-Jun-2019	Offer Document

18-Jun-2019	Appendix 3B

18-Jun-2019	Capital Raising and Board Changes

14-Jun-2019	Trading Halt

3-Jun-2019	EUROPEAN PATENT VALIDATED

27-May-2019	R&D Tax Incentive Refund

1-May-2019	U.S. Patent Issued

30-Apr-2019	Appendix 4C - quarterly

1-Apr-2019	Response to ASX Price and Volume Query

28-Feb-2019	Half Yearly Report and Accounts

15-Feb-2019	Cancer Vaccine Study Results

25-Jan-2019	Quarterly Business Update and Appendix 4C

18-Dec-2018	Change in Substantial Holding

18-Dec-2018	Change of Directors Interest - Irminger-Finger

18-Dec-2018	Change of Directors Interest - Montgomery

18-Dec-2018	Change of Directors Interest - Gunzburg

18-Dec-2018	Shortfall Confirmation and Appendix 3B

12-Dec-2018	Closure of Entitlement Offer and Shortfall

3-Dec-2018	Change of Director's Interest Notice

30-Nov-2018	Results of Meeting

30-Nov-2018	AGM Presentation

27-Nov-2018	Despatch of Offer Document

20-Nov-2018	Letters to Shareholders

20-Nov-2018	Appendix 3B

19-Nov-2018	Cleansing Notice Rights Issue

19-Nov-2018	Rights Offer Document

19-Nov-2018	Company Presentation

19-Nov-2018	Appendix 3B

12-Nov-2018	Capital Raising Indicative Timetable

8-Nov-2018	Non-Renounceable Issue

7-Nov-2018	Trading Halt

7-Nov-2018	Pause In Trading

31-Oct-2018	Ceasing to be a substantial holder

31-Oct-2018	Quarterly Activities Report and Cashflow

30-Oct-2018	Notice of Annual General Meeting/Proxy Form

29-Oct-2018	Change in substantial holding

24-Oct-2018	Becoming a substantial holder

24-Oct-2018	Grant of Additional Chinese Patent Core BARD1 Patent Family

23-Oct-2018	Development of world first BARD1 Breast Cancer Test

1-Oct-2018	Appendix 4G

1-Oct-2018	Annual Report to Shareholders

20-Sep-2018	Investor Presentation and Update

10-Sep-2018	Ceasing to be a substantial holder

6-Sep-2018	Bard1 Ovarian Test Results

31-Aug-2018	Appendix 4E

21-Aug-2018	Final Director's Interest Notice

13-Aug-2018	Death of Non-Executive Director

1-Aug-2018	Quarterly Activities Report and Appendix 4C

12-Jul-2018	US Patent Issued Protecting BARD1 Ovarian Test

21-Jun-2018	Appendix 3B Release of Securities from Escrow

19-Jun-2018	Improved Performance of BARD1 Ovarian Test

8-Jun-2018	Notice under ASX Listing Rule 3.10A

18-May-2018	Reinstatement to Official Quotation

18-May-2018	Response to ASX Price Query

18-May-2018	Contract Development Agreement Signed

14-May-2018	Voluntary Suspension

10-May-2018	Trading Halt

30-Apr-2018	Quarterly Business Update and Appendix 4C

19-Apr-2018	Becoming a substantial holder

28-Mar-2018	Appendix 3B and Cleansing Statement

22-Mar-2018	Corporate Presentation

22-Mar-2018	Capital Raising

21-Mar-2018	Israeli Patent Issued in Bard1 Core Patent Family

20-Mar-2018	Trading Halt

6-Mar-2018	Additional BARD1 Ovarian Test Results

28-Feb-2018	Half Yearly Report and Accounts

20-Feb-2018	Appendix 3B (Advisor Options)

2-Feb-2018	Grant of Japanese Patent

30-Jan-2018	Quarterly Business Update and Appendix 4C

9-Jan-2018	RESULTS OF BARD1 OVARIAN CANCER STUDY

28-Nov-2017	Results of Meeting

28-Nov-2017	AGM Presentation

30-Oct-2017	Quarterly Business Update and Appendix 4C

27-Oct-2017	Notice of Annual General Meeting

4-Oct-2017	Research and Development Update

29-Sep-2017	Appendix 4G

29-Sep-2017	Annual Report to Shareholders

31-Aug-2017	Appendix 4E Preliminary Financial Results

8-Aug-2017	Publication of BARD1 Lung Cancer Test

7-Aug-2017	Appendix 3B

7-Aug-2017	Australian Patent Issued

4-Aug-2017	Completion of Share Purchase Plan

27-Jul-2017	Quarterly Activities Report & Appendix 4C

20-Jul-2017	Appointment of Dr Samuel Janes

11-Jul-2017	Completion of Capital Raising

11-Jul-2017	Appendix 3B and Cleansing Notice

11-Jul-2017	Share Purchase Plan Cleansing Statement

11-Jul-2017	Share Purchase Plan Document

5-Jul-2017	Capital Raising

3-Jul-2017	Trading Halt

28-Jun-2017	Shareholder Update

15-May-2017	Lung Cancer Study Results

28-Apr-2017	Quarterly Activities Report and Appendix 4C

18-Apr-2017	Shareholder Update

5-Apr-2017	Cancer Vaccine Collaboration

29-Mar-2017	Appendix 3B

23-Mar-2017	OVARIAN CANCER CLINICAL STUDY RESULTS

23-Mar-2017	GRANT OF U.S. PATENT

28-Feb-2017	Appendix 4D and Half Yearly Reports and Accounts

8-Feb-2017	Successful Assay Feasibility Results

31-Jan-2017	Quarterly Activities Review and Appendix 4C

8-Nov-2016	CEO Terms of Employment

7-Nov-2016	AGM RESULTS

7-Nov-2016	AGM PRESENTATION

3-Nov-2016	Appointment of CEO

31-Oct-2016	Quarterly Activities Report and Appendix 4C

19-Oct-2016	Appendix 4G

19-Oct-2016	Annual Report to Shareholders

7-Oct-2016	Notice of Annual General Meeting/Proxy Form

30-Sep-2016	Statutory Audited Financial Statements

22-Sep-2016	Company Update - Promising Result for Ovarian Cancer

31-Aug-2016	Preliminary Final Report - Appendix 4E

4-Aug-2016	Appendix 3Y - Gunzburg

2-Aug-2016	Appendix 3Y - Gunzburg

28-Jul-2016	Quarterly Activities Report and Appendix 4C

14-Jul-2016	Appendix 3Y - Gunzburg

12-Jul-2016	Appendix 3Y - Gunzburg

12-Jul-2016	Becoming a Substantial Holder - Walker

6-Jul-2016	Appendix 3Y - Gunzburg

30-Jun-2016	Appendix 3Y - Gunzburg

28-Jun-2016	Appendix 3Y - Gunzburg

21-Jun-2016	Appendix 3Y - Gunzburg

20-Jun-2016	Appendix 3Y - Gunzburg

20-Jun-2016	Becoming a substantial holder

17-Jun-2016	Confirmations to ASX

17-Jun-2016	Terms of Securities

17-Jun-2016	Confirmation in relation to restricted securities

17-Jun-2016	Securities Trading Policy

17-Jun-2016	Use of Funds Information

17-Jun-2016	Pro-forma Statement of Financial Position

17-Jun-2016	BARD1AG Financial Statements 2015

17-Jun-2016	BARD1AG Financial Statements 2014

17-Jun-2016	BARD1AG Financial Statements 2013

17-Jun-2016	Constitution

17-Jun-2016	Appendix 1A and Information Form & Checklist

17-Jun-2016	Capital Structure

17-Jun-2016	Top 20 Shareholders

17-Jun-2016	Distribution Schedule

17-Jun-2016	Pre-reinstatement Disclosure

17-Jun-2016	ASX Notice

17-Jun-2016	Reinstatement to Official Quotation - 20 June 2016

16-Jun-2016	Appendix 3Z - Collinson

16-Jun-2016	Appendix 3X - Laurent

16-Jun-2016	Appendix 3X - Irminger

16-Jun-2016	Appendix 3Y - Gunzburg

16-Jun-2016	Appendix 3B

8-Jun-2016	Receipt of Signed Restriction Agreement

3-Jun-2016	Extension to deadline for automatic removal

27-May-2016	Capital Raising Closed Oversubscribed

29-Apr-2016	Quarterly Activities Report and App 5B

7-Apr-2016	Replacement Prospectus

24-Mar-2016	Results of Meeting

24-Mar-2016	PROSPECTUS

24-Feb-2016	Notice of General Meeting

29-Jan-2016	Quarterly Activities Report and Appendix 5B

29-Jan-2016	Half Year Accounts

1-Dec-2015	Proposed Acquisition and Capital Raising

30-Nov-2015	Results of Annual General Meeting

30-Oct-2015	Appendix 4G

30-Oct-2015	Annual Report to shareholders

30-Oct-2015	Notice of Annual General Meeting/Proxy Form

28-Oct-2015	Quarterly Activities and Cashflow Report

1-Oct-2015	Full Year Statutory Accounts

31-Jul-2015	Quarterly Activities and Cashflow Report

22-Jun-2015	Details of Share Registry address

28-Apr-2015	Quarterly Cashflow & Activities Report

17-Mar-2015	Appendix 3B

17-Mar-2015	Half Yearly Report and Accounts

30-Jan-2015	Quarterly Activities Report and Cashflow

30-Jan-2015	Appendix 3B

30-Dec-2014	Change in substantial holding

24-Dec-2014	Top 20 securityholders

24-Dec-2014	Change in substantial holding

24-Dec-2014	Change of Director's Interest Notice

24-Dec-2014	Appendix 3B

8-Dec-2014	Updated Timetable Non-Renounceable Rights Issue

8-Dec-2014	Extension of Non-Renounceable Rights Issue

2-Dec-2014	Despatch of Non-Renounceable Rights Issue Prospectus

26-Nov-2014	Letter to Ineligible Shareholders

26-Nov-2014	Letter to Eligible Shareholders

26-Nov-2014	Results of Meeting

25-Nov-2014	Becoming a substantial holder

25-Nov-2014	Appendix 3B

25-Nov-2014	Prospectus

21-Nov-2014	Substantial Shareholders Notice - Montgomery

20-Nov-2014	Becoming a Substantial Shareholder - Cheung

20-Nov-2014	Ceasing to be a substantial holder

19-Nov-2014	Change of Director's Interest - Gunzburg

19-Nov-2014	Initial Director's Interest - Collinson

19-Nov-2014	Initial Director's Interest - Montgomery

17-Nov-2014	Final Directors' Interests - Dew-Procter-Wong

17-Nov-2014	Company Update

30-Oct-2014	Annual Report to Shareholders

24-Oct-2014	Quarterly Activities and Cashflow Report

24-Oct-2014	Notice of AGM and Proxy Form

2-Oct-2014	Completion of Dragon Share Offer

1-Oct-2014	Full Year Statutory Accounts

1-Sep-2014	Offer Document

1-Sep-2014	Sale of Shares in Dragon Mining

8-Aug-2014	Company Update

30-Jul-2014	Quarterly Cashflow and Activities Report

29-Apr-2014	Quarterly Cashflow and Activities Report

14-Mar-2014	Half Year Accounts

7-Feb-2014	Takeovers Panel Decision (Dragon Mining)

31-Jan-2014	Quarterly Activities and Cashflow Report

9-Dec-2013	Company Update

20-Nov-2013	Results of Meeting

29-Oct-2013	Quarterly Cashflow and Activities Report

18-Oct-2013	Notice of Annual General Meeting/Proxy Form

16-Oct-2013	Annual Report to shareholders

27-Sep-2013	Full Year Statutory Accounts

19-Jul-2013	Quarterly Cashflow and Activities Report

11-Jun-2013	Company Update

4-Jun-2013	Suspension from Official Quotation

3-Jun-2013	Trading Halt Request

3-Jun-2013	Trading Halt

16-May-2013	Company Update

30-Apr-2013	Quarterly Activities Report and Cashflow

21-Mar-2013	Change of Director's Interest Notice

18-Mar-2013	Half Year Accounts

31-Jan-2013	Quarterly Activities and Cashflow Report

2-Jan-2013	New Contact Numbers

18-Dec-2012	Details of Company Address

7-Dec-2012	Initial Director's (Alternate) Interest Notice

7-Dec-2012	Appointment of Alternate Director

30-Nov-2012	Initial Director's Interest Notice

30-Nov-2012	Final Director's Interest Notice

29-Nov-2012	Director Appointment/Resignation

26-Nov-2012	Results of Meeting

5-Nov-2012	Reinstatement to Official Quotation

2-Nov-2012	Annual Report to shareholders

31-Oct-2012	Quarterly Cashflow and Activities Report

26-Oct-2012	Notice of Annual General Meeting/Proxy Form

23-Oct-2012	Initial Director's Interest Notice

23-Oct-2012	Final Director's Interest Notice

23-Oct-2012	Director Appointment/Resignation

28-Sep-2012	Full Year Statutory Accounts

31-Jul-2012	Quarterly Activities and Appendix 5B

27-Apr-2012	Quarterly Activities and Cashflow Report

16-Mar-2012	Company Update - Dragon Mining Ltd Rights Issue

15-Mar-2012	Revised Half Yearly Report and Financials

15-Mar-2012	Half Yearly Report and Accounts

29-Feb-2012	Company Update

6-Feb-2012	Dragon Mining Rights Issue Subunderwriting

25-Jan-2012	Quarterly Cashflow and Activities Report

15-Nov-2011	Results of Meeting

11-Nov-2011	Change in substantial holding

28-Oct-2011	Annual Report to shareholders

19-Oct-2011	Quarterly Activities and Cashflow Report

17-Oct-2011	Notice of Annual General Meeting/Proxy Form

10-Oct-2011	Amended Directors Interest Amended

10-Oct-2011	Change of Director's Interest Notice

30-Sep-2011	Full Year Statutory Accounts

30-Sep-2011	Full Year Statutory Accounts

27-Sep-2011	Becoming a substantial holder

21-Jul-2011	Quarterly Activities and Cashflow Report

28-Apr-2011	Quarterly Cashflow and Activities Report

12-Apr-2011	Change of Director's Interest Notice

15-Mar-2011	Half Yearly Report and Accounts

10-Mar-2011	Change of Director's Interest Notice

1-Mar-2011	Half Yearly Accounts

14-Feb-2011	Revised Quarterly Appendix 5B

31-Jan-2011	Quarterly Cashflow and Activities Reports

4-Jan-2011	Letter to Shareholders re Unmarketable Parcel of Shares

31-Dec-2010	Securities Trading Policy

22-Dec-2010	Change of Director's Interest Notice

22-Dec-2010	Change of Director's Interest Notice

22-Dec-2010	Appendix 3B

8-Dec-2010	Change in substantial holding

8-Dec-2010	Change in substantial holding

2-Dec-2010	Appendix 3B

24-Nov-2010	Brinkley Mining Takeover

8-Nov-2010	Results of Annual General Meeting

8-Nov-2010	Results of General Meeting

2-Nov-2010	Quarterly Cashflow Report - Replacement

21-Oct-2010	Acquisition of Brinkley Mining Plc by Scheme of Arrangement

12-Oct-2010	Quarterly Activities and Appendix 5B

7-Oct-2010	Annual Report to shareholders

7-Oct-2010	Notice of Annual General Meeting/Proxy Form

7-Oct-2010	Notice of General Meeting/Proxy Form

9-Sep-2010	Acquisition of Brinkley Mining PLC by Scheme of Arrangement

8-Sep-2010	Full Year Statutory Accounts

2-Sep-2010	Repayment of Loan by Tanami Gold NL

22-Jul-2010	Quarterly Cashflow and Activities Report

27-May-2010	Change of Director's Interest Notice

6-May-2010	Change of Director's Interest Notice

4-May-2010	Change of Director's Interest Notice

29-Apr-2010	Quarterly Cashflow Report

14-Apr-2010	Change of Director's Interest Notice

12-Apr-2010	Change of Director's Interest Notice

30-Mar-2010	A$5 million loan facility toTanami Gold NL

16-Mar-2010	Half Yearly Accounts

5-Feb-2010	Interest in Brinkley Mining Plc

29-Jan-2010	Quarterly Activities Report and Appendix 5B

27-Jan-2010	Brinkley Mining/Eurogold interest in Dragon Mining Limited

7-Dec-2009	Brinkley Mining Plc Minority interest in Dragon Mining Ltd

13-Nov-2009	Results of Meeting

28-Oct-2009	Annual Report to shareholders

27-Oct-2009	Updated Net Asset Position

21-Oct-2009	Change in substantial holding

12-Oct-2009	September 2009 Quarterly Cashflow and Activities Report

12-Oct-2009	Notice of Annual General Meeting/Proxy Form

30-Sep-2009	Full Year Statutory Accounts

24-Aug-2009	Investment in Brinkley Mining PLC

16-Jul-2009	Quarterly Cashflow Report

3-Jul-2009	Response to ASX Query re Appendix 3Y

2-Jul-2009	Change of Director's Interest Notice

12-Jun-2009	Update on recent activities

11-Jun-2009	Request for Trading Halt

11-Jun-2009	Trading Halt

24-Apr-2009	Quarterly Activities Report

26-Feb-2009	Half Year Accounts

14-Jan-2009	Quarterly Activities and Cashflow Report

16-Dec-2008	Appendix 5B

13-Nov-2008	Results of Meeting

28-Oct-2008	Annual Report to shareholders

17-Oct-2008	Quarterly Activities and Cashflow Reports

15-Oct-2008	Notice of Annual General Meeting/Proxy Form

7-Oct-2008	Change of Director's Interest Notice

7-Oct-2008	Change of Director's Interest Notice

7-Oct-2008	Change of Director's Interest Notice

24-Sep-2008	Change in substantial holding

18-Sep-2008	Full Year Statutory Accounts

17-Sep-2008	Appendix 5B - Monthly

9-Sep-2008	Becoming a substantial holder

8-Sep-2008	Allotment of Shares re Non-Renounceable Issue

5-Sep-2008	Non-Renounceable Issue

4-Sep-2008	Completion of Non-Renounceable Issue

18-Aug-2008	Appendix 5B - Monthly

12-Aug-2008	ASX Circular: Reorganisation of Capital

12-Aug-2008	Results of Meeting

1-Aug-2008	Supplementary Prospectus

1-Aug-2008	Quarterly Activities Report

30-Jul-2008	Change in substantial holding

24-Jul-2008	Revised Timetable Non-Renounceable Rights Issue

23-Jul-2008	Change of Director's Interest Notice

22-Jul-2008	Change of Director's Interest Notice

22-Jul-2008	Change of Director's Interest Notice

15-Jul-2008	Appendix 5B

14-Jul-2008	Notice of General Meeting/Proxy Form

14-Jul-2008	Despatch of Prospectus

7-Jul-2008	Non-Renounceable Rights Issue - Revised Prospectus

4-Jul-2008	Letter to Shareholders

3-Jul-2008	Prospectus

24-Jun-2008	Non-Renounceable Rights Issue and Share Consolidation

16-Jun-2008	Monthly Financials

22-May-2008	Settlement with Oxus Gold Plc

15-May-2008	Monthly Financials

9-May-2008	Settlement with Oxus Gold Plc

15-Apr-2008	Quarterly Activities

2-Apr-2008	Settlement with Oxus Gold

17-Mar-2008	Monthly Financials

14-Mar-2008	Half Yearly Report and Accounts

3-Mar-2008	Ceasing to be a substantial holder

27-Feb-2008	Becoming a substantial holder

26-Feb-2008	Ceasing to be a substantial holder

21-Feb-2008	Ceasing to be a substantial holder

19-Feb-2008	Settlement of Federal Court Proceedings Against Oxus Gold

18-Feb-2008	Trading Halt

15-Feb-2008	Monthly Financials

31-Jan-2008	Quarterly Activities and Cashflow Report

15-Jan-2008	Appendix 5B - Monthly

17-Dec-2007	Appendix 5B

15-Nov-2007	Appendix 5B

15-Nov-2007	Results of Meeting

15-Nov-2007	Results of Meeting

30-Oct-2007	Annual Report to shareholders

16-Oct-2007	Notice of Annual General Meeting/Proxy Form

15-Oct-2007	Quarterly Activities Report

28-Sep-2007	Full Year Accounts

13-Sep-2007	Appendix 5B

5-Sep-2007	Change of Director's Interest Notice

30-Jul-2007	Quarterly Activities Report

10-Jul-2007	Results of Meeting

9-Jul-2007	Details of Company Address

8-Jun-2007	Notice of General Meeting

6-Jun-2007	Change of Director's Interest Notice

6-Jun-2007	Change of Director's Interest Notice

6-Jun-2007	Change of Director's Interest Notice

28-May-2007	Federal Court Dismissed Motion

22-May-2007	Proposed Sale of Assets

21-May-2007	Company's request for trading halt

21-May-2007	Trading Halt

30-Apr-2007	Third Quarter Activities & Cashflow Reports

29-Mar-2007	Loan Repayment

21-Mar-2007	Termination of Agreement to Purchase Saulyak Gold Mine

16-Mar-2007	Half Year Accounts

26-Feb-2007	Proposed Sale of Gold Assets to Dargon Mining Ltc

31-Jan-2007	Second Quarter Activities & Cashflow Reports

22-Jan-2007	Change in substantial holding